Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when AVR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsAnteris exits v2vmedtech partnership, pays $400k break fee; equity stake may be bought back
Filed April 29, 2026 · Period ending April 29, 2026 · ~1 min read
Key Changes
-
high
Anteris terminated its 2023 development agreement with v2vmedtech after completing Stage 1, ending all future development contributions and operational ties to the partnership.
Item 1.01 view on EDGAR → -
high
v2vmedtech's original shareholders can either buy out Anteris' entire equity stake at cost or dilute the company to a capped minority position; the choice and financial impact remain undisclosed.
Item 1.01 view on EDGAR → -
medium
Anteris will pay a one-time $400,000 break fee to v2vmedtech, which will use the funds to continue developing the technology independently.
Item 1.01 view on EDGAR → -
medium
Management states the exit will not materially affect Anteris' financial position or liquidity, suggesting the partnership was not core to strategy.
Item 1.01 view on EDGAR →
Summary
Anteris Technologies has walked away from a three-year-old development partnership with v2vmedtech, notifying the partner on April 28 that it would make no further contributions beyond Stage 1 of the program. The exit triggers a $400,000 break fee and gives v2v's founders the option to either buy back Anteris' equity stake at cost or dilute the company to a minority position. Management has not disclosed the total invested to date or which option v2v will choose.
The company characterizes the exit as immaterial to its finances, implying the v2vmedtech technology was not central to Anteris' core valve business. For retail holders, the key question is whether this signals a strategic pivot or simply housekeeping on a non-core asset. Watch the next quarterly filing for details on the equity disposition and any write-downs, and listen for management commentary on capital allocation priorities going forward.
Section-by-Section Diff
Event · Item 1.02 — Termination of a Material Definitive Agreement
Anteris terminated development agreement with v2vmedtech, paying $400k break fee; v2v shareholders may buy back Anteris' equity stake.
Added in current filing · verify on EDGAR →
On April 28, 2026, Anteris Technologies Global Corp., through its wholly owned subsidiary, Anteris Technologies Corporation (the “Company”), notified v2vmedtech, inc. (“v2v”) of its election to discontinue additional development contributions under the Contribution and Stock Purchase Agreement dated April 18, 2023 (the “Agreement”).
Anteris elected to exit a development partnership with v2vmedtech after completing Stage 1 and during Stage 2 of the development program. This terminates the company's obligation to make further development contributions under the original 2023 agreement.
Added in current filing · verify on EDGAR →
The initial shareholders of v2v have the right, at their election, to either: ... acquire all of the Company’s equity interest in v2v for an amount equal to the Company’s aggregate contributions to date, or ... reduce the Company’s equity interest in v2v to a capped minority ownership percentage as specified in the Agreement.
v2v's initial shareholders can choose to either buy out Anteris' entire equity stake at cost or dilute Anteris down to a capped minority position. The company has not yet disclosed which option v2v will select or the total amount of $400,000 Anteris' contributions to date.
Added in current filing · verify on EDGAR →
In addition, as a result of the termination of the Company’s obligation to make further development contributions to v2v under the Agreement, the Development Agreement by and between the Company, dated as April 18, 2023 (the “Development Agreement”), will terminate upon the payment of the $400,000 break fee.
A separate Development Agreement from April 2023 will also terminate once the break fee is paid, fully ending the operational relationship between Anteris and v2vmedtech.
Added in current filing · verify on EDGAR →
The Company does not expect the discontinuation of contributions under the Agreement and the termination of the Development Agreement to have a material adverse effect on its consolidated financial position or liquidity.
Management states the termination will not materially harm Anteris' financial position or liquidity, suggesting the v2vmedtech partnership was not a core strategic asset and the break fee and potential equity buyback are manageable.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify